Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume
New targeted pill offers hope for adults and teens with moderate-to-severe plaque psoriasis
The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials
These approvals represent a defining moment for people living with classical Hodgkin Lymphoma
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
The initiative will focus on creating healthier early-life environments, promoting physical activity, identifying risks early, and strengthening preparedness within primary health care systems
AA, a chronic immune disease, can cause extensive and unpredictable hair loss
The approval is based on the SWIFT and ANCHOR phase III trials, which demonstrated sustained efficacy with a twice-yearly dosing regimen
HYMPAVZI is already approved in the US for patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors
The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
Subscribe To Our Newsletter & Stay Updated
